Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7441 to 7455 of 7686 results

  1. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

    This evidence summary has been updated and replaced by NICE guideline NG201.

    Evidence summary
    Published
    24 June 2019

  2. Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]

    Discontinued [GID-TA10996]

    Technology appraisal guidance
    Discontinued

  3. Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]

    Discontinued [GID-TA10995]

    Technology appraisal guidance
    Discontinued

  4. Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]

    Discontinued [GID-TA11108]

    Technology appraisal guidance
    Discontinued

  5. Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]

    Discontinued [GID-TA10937]

    Technology appraisal guidance
    Discontinued

  6. Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]

    Discontinued [GID-TA10965]

    Technology appraisal guidance
    Discontinued

  7. Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]

    Discontinued [GID-TA10863]

    Technology appraisal guidance
    Discontinued

  8. Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]

    Discontinued [GID-TA10766]

    Technology appraisal guidance
    Discontinued

  9. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    Discontinued [GID-TA11004]

    Technology appraisal guidance
    Discontinued

  10. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    Discontinued [GID-TA11020]

    Technology appraisal guidance
    Discontinued

  11. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued [GID-TA11244]

    Technology appraisal guidance
    Discontinued

  12. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    Discontinued [GID-TA10958]

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued [GID-TA10583]

    Technology appraisal guidance
    Discontinued

  14. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]

    Discontinued [GID-TA10525]

    Technology appraisal guidance
    Discontinued

  15. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    Discontinued [GID-TA10185]

    Technology appraisal guidance
    Discontinued